New Brain Research Finds Cognizin® Suppresses Craving

The obesity crisis in the United States has now grown to epidemic proportion. And as the list of consequential health conditions and diseases continues to expand as well, there are major movements toward helping Americans lose weight. Perhaps the next ally in battling poor appetite control is a vitamin-like nutrient called citicoline. Scientists at McLean Hospital and professors at Harvard Medical School have explored the effects of Cognizin® citicoline supplementation on the neurobiological systems involved in appetite and eating behavior regulation and found the potential to reduce cravings and increase feelings of satiety. This work was published in the January issue of the International Journal of Eating Disorders.

While an Associate Professor of Psychiatry at Harvard Medical School and McLean Hospital, and researcher on this study Deborah Yurgelun-Todd PhD, monitored the effect of nutrients such as citicoline on the dopamine neurons in the brain, which have been shown to have a direct effect on the motivation to eat and the rewarding value of food. She explains, "We know that appetitive responses are highly regulated by homeostatic mechanisms in the hypothalamus portion of the brain, including hormones and dopamine. Previous research has measured the effect that hormones and dopamine - and nutrients like citicoline that may increase these compounds - may have in a variety of substance abuse and addictive behavior disorders such as cocaine addiction and pathological gambling. In this latest study, we applied a similar set of theories to study citicoline and both regulation of food intake and motivation to eat."

This study compared the effects of open label treatment with citicoline at two different dosages (500 mg/day versus 2,000 mg/day) for six weeks on changes in appetite ratings (using questionnaires), weight, and brain response to images of high-calorie foods (using magnetic resonance imaging). In the stimulation phases of the study, at baseline and following the 6-week treatment, participants were monitored via MRI while viewing a series of colorful visuals that included both high-calorie foods and non-food objects in a quick 150-second series of photos. Each image was viewed for a brief, three seconds. Study participants included 16 healthy adults (8 men, 8 women) ranging from 40 to 57 years of age, and across a range of Body Mass Index values from 20 to 38.

Appetite ratings did decline significantly for the group as a whole, as assessed by questionnaire responses. The decline for the high-dose group did reach significance, however the low-dose group did not. There was no significant weight change in weight for either group overall, although individuals did show weight loss. "The most interesting findings are that with the use of brain imaging studies, we are able to visualize the differences between baseline and after 6-weeks of citicoline supplementation. Scans from the high-dose group illustrate the shift in how their brains interpreted the food images," explains Yurgelun-Todd, now the Director of the Cognitive Neuroimaging Laboratory and The Brain Institute at the University of Utah.

There are three regions of the brain that are particularly relevant to appetite control and behavioral inhibition: the lateral orbitofrontal cortex, the insular cortex and the amygdala. In a direct correlation, those high-dose participants who had the greatest activation of these three portions of the brain saw the greatest decline in appetite for high-calorie foods. "The citicoline may have affected their appetite by stimulating regions of the brain used to normalize or regulate their response to the food images. These three regions may help the participant see food as less rewarding, and therefore have a lesser desire to eat it," added Yurgelun-Todd.

Citicoline has a number of different mechanisms of action, and it has yet to be determined which may be responsible for the changes in brain responses. The vitamin-like nutrient has been known to function as a precursor of phospholipid and acetylcholine synthesis; citicoline also enhances of the release of neurotransmitters such as norepinephrine and increased synthesis of phospholipids including cardiolipin and sphingomyelin. Citicoline has also been recognized for neuroprotective effects with stroke or other brain injuries, protection from cognitive decline. Though this research is still preliminary, researchers will continue to investigate whether these effects are related to citicoline properties, or from the effect citicoline has on the dopamine or other systems.

Cognizin® Citicoline is currently available in the U.S. in a number of supplements formulated to support brain health, including Jarrow Formulas, Swanson Health Products, Nutraceutical Sciences Institute (NSI) products, Healthy Origins, AOR CDP-Citicoline, Life Extension, SomaLife, JoJo Energy, Metabolic Maintenance and many more.

In addition to Cognizin Citicoline, Kyowa is the maker of other leading branded ingredients including Hydrafend™ Hyaluronic Acid, Lumistor® L-Hydroxyproline, Kyowa CoQ10®, Setria® Glutathione and Sustamine™ Alanyl Glutamine. Kyowa offers manufacturers and formulators one of the industry's most extensive lines of over 50 amino acids and related compounds, including D-Amino acids and branch-chain amino acids, as well as nucleic acids, bio-products and fine chemicals.